PULSE BIOSCIENCES - Key Persons

Job Titles:

• Chief Technology Officer
• Director
• Member of the Management Team
• Chief Executive Officer and President and a Director

Darrin R. Uecker was appointed Pulse Biosciences Chief Technology Officer in September 2022, having previously served as the Company's Chief Executive Officer & President since September 2015. Mr. Uecker has over 30 years of experience in the medical device field and is a named inventor on over 70 patents. Prior to Pulse Biosciences Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc., Menlo Park, California, a company that developed Eeva™, the world's first automated time-lapse system for embryo selection during in-vitro fertilization. Prior to that Mr. Uecker was the Chief Executive Officer and President and a Director of Gynesonics, Inc., Redwood City, California, a company that developed a novel medical device for the treatment of symptomatic uterine fibroids using ultrasound guided radiofrequency ablation. Mr. Uecker has served in a variety of executive level roles at CyberHeart, Inc., Conceptus, Inc., RITA Medical Systems, Inc., and Computer Motion, Inc. Mr. Uecker attended the University of California at Santa Barbara where he received a B.S. and M.S. in electrical and computer engineering.

Job Titles:

• Member of the Management Team
• Senior VP of Engineering
• VP of Engineering

David Danitz joined Pulse Biosciences in November 2015 as VP of Engineering. Mr. Danitz has over 20 years of medical device development experience and is the named inventor on over 50 US patents. Prior to Pulse Biosciences he held the position of Vice President, R&D - Custom Products at Earlens, where he led the development of a light-driven transducer that directly engaged the ear drum to generate sound. Before that, Mr. Danitz held the position of Vice President R&D for Gynesonics, where he led the development of the world's first intrauterine ultrasound system with integrated RF ablation for an incisionless treatment of uterine fibroids. Mr. Danitz also served at Novare Surgical as Vice President of R&D where for 10 years his team brought medical devices to the market in the areas of cardiac, vascular, general, urologic and gynecologic surgery. Mr. Danitz has received several Medical Design Excellence Award's. Mr. Danitz earned a BSME degree with high honors from the University of California at Santa Barbara, and a SMME degree from the Massachusetts Institute of Technology.

Job Titles:

• Member of the Management Team
• Vice President of Operations
• VP of Operations

Edison Manuel joined Pulse Biosciences in April 2017 as VP of Operations. Mr. Manuel has over 30 years of experience and held several senior level positions with the last 22 years focused on medical devices ranging from robotics, RF ablation systems, motion hand-held laparoscopic instruments and time-lapse imaging system. Mr. Manuel brings extensive experience in operations from start-up manufacturing into full commercial release, program management, factory integration and consolidation, strategic outsourcing and supply chain management. Prior to joining Pulse, he held similar positions at Progyny, Stellartech Research Corp and Novare Surgical Systems. Mr. Manuel also held senior level positions RITA Medical Systems and Computer Motion, Inc. Mr. Manuel earned a B.S. degree in Management and Industrial Engineering at Mapua Institute of Technology, Manila, Philippines.

Job Titles:

• Corporate Secretary
• General Counsel

Ken Stratton, J.D., joined Pulse Biosciences in May 2021 as General Counsel and Corporate Secretary. Mr. Stratton brings more than 25 years of wide-ranging legal experience, including having led legal affairs at multiple publicly-traded life science companies. Prior to joining Pulse Biosciences, Mr. Stratton was General Counsel of StemCells, Inc., Deputy General Counsel of Threshold Pharmaceuticals, Inc., and Senior Legal Counsel at Medtronic's Vascular Business Unit. As the senior most legal counsel, he has handled all aspects of life science law including compliance, IP licensing and commercial partnering. Prior to working in-house, Mr. Stratton was a corporate transactional attorney at Gibson Dunn & Crutcher, a leading global law firm, and an employment litigator at Littler Mendelson, the largest labor and employment law firm. Most recently, he was a Partner at Rogoway Law Group, a specialty life science firm. Mr. Stratton earned his undergraduate degrees from the University of Pennsylvania, his M.B.A. in Finance from the Stern School of Business at N.Y.U., and his J.D. from the New York University School of Law.

Job Titles:

• Chief Executive Officer
• Member of the Management Team
• President

Kevin Danahy was appointed Pulse Biosciences President and Chief Executive Officer in September 2022, having previously served as the Company's Chief Commercial Officer since February 2022. Mr. Danahy has more than 20 years of senior leadership experience building and leading strategic commercial organizations for medical technology companies. Prior to joining Pulse Biosciences, Mr. Danahy served as President of Solmetex, driving revenue growth for the company through the implementation of innovative and scalable solutions, while overseeing strategy, sales, marketing, operations, engineering, and service efforts. Previously, at Zimmer Biomet, Mr. Danahy held roles of increasing responsibility, most recently as Vice President of Global Emerging Technologies and Specialty Sales. Before his time at Zimmer, Mr. Danahy served as Senior Director at Intuitive Surgical, where he successfully transformed the sales leadership training program. Early in his career, he served in commercial leadership roles at both Medtronic and Johnson & Johnson. Mr. Danahy holds a Master's of Science from Tufts University.

Job Titles:

• Chairman of the Audit Committee
• Chairman of the Compensation Committee
• Chairman of the Nominating and Corporate Governance Committee
• Member of the Board of Directors
• Audit Committee
• Chief Financial Officer and Executive Vice President of Reata Pharmaceuticals, Inc

Manmeet S. Soni was appointed to our Board of Directors in November 2017. Mr. Soni currently serves as Chief Financial Officer and Executive Vice President of Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. From May 2017 to August 2019, Mr. Soni served as Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals. From March 2016 to February 2017, Mr. Soni served as Chief Financial Officer and Treasurer of biopharmaceutical company ARIAD Pharmaceuticals, Inc., where he played a central role in the strategic review, turnaround, and subsequent acquisition of ARIAD Pharmaceuticals, Inc. by Takeda Pharmaceutical Company Limited. Before joining ARIAD Pharmaceuticals, Inc., Mr. Soni joined Pharmacyclics, Inc. in 2012 as Corporate Controller and held various other roles there until becoming Chief Financial Officer and Treasurer in February 2014. He also played a vital role in the acquisition of Pharmacyclics, Inc. by AbbVie, Inc. for $21 billion. Previously, Mr. Soni worked at Zeltiq Aesthetics, Inc., and PricewaterhouseCoopers San Jose, in the Life Science and Venture Capital Group. Prior to that, he worked at PricewaterhouseCoopers India. Mr. Soni graduated from Hansraj College at Delhi University in India. He is recognized as a Certified Public Accountant, licensed by the State of California, and as a Chartered Accountant in India. Mr. Soni currently serves as director of Arena Pharmaceuticals, Inc. and Summit Therapeutics plc.

Job Titles:

• Chief Strategy Officer
• Member of the Management Team

Mitchell E. Levinson joined as Chief Strategy Officer of Pulse Biosciences in August 2021 and continues in his role on our Board of Directors. Mr. Levinson served on the board from January 2015 to November 2017 and then returned March 2019 to May 2023. Mr. Levinson has over 30 years of experience developing and launching novel medical device technologies across multiple medical disciplines, including dermatology, wound care, surgery, diagnostics, otolaryngology, microbiology, neurology, OB/GYN, patient monitoring and digital health. Most recently, he co-founded and served as startup CEO for Cerebrotech Medical Systems where he led the development of a novel brain monitor. Mr. Levinson was the first employee and startup CEO for Zeltiq Aesthetics, the CoolSculpting company, acquired by Allergan in 2017. Prior to Zeltiq, he held executive R&D positions at Thermage and BioSurgical Corporation. Mr. Levinson currently sits on the boards of directors for several medical technology startup companies. He is an inventor on over 50 issued and numerous pending U.S. patents. Mr. Levinson earned his B.S. in Mechanical Engineering from University of California at San Diego and holds an M.S. in Computer Systems from the University of Phoenix.

Job Titles:

• Member of the Management Team
• Vice President of Human Resources

Patty Perla joined Pulse Biosciences in March 2020 as Vice President of Human Resources. Ms. Perla brings over 15 years of experience in human resources building diverse, high performing organizations in the life science industry. Her expertise extends across the spectrum of human resources, including talent development, culture initiatives and innovative total rewards strategies. Prior to joining Pulse, Ms. Perla has held various leadership roles with small and mid-size companies including Ceterix Orthopaedics (acquired by Smith and Nephew), Revance Therapeutics, Ventus Medical and FoxHollow Technologies (acquired by EV3). Ms. Perla earned a B.S. degree in Management from Golden Gate University in San Francisco.

Job Titles:

• Chief Science Officer
• Member of the Management Team

Richard Nuccitelli, Ph.D. has been our Chief Science Officer since November, 2014. He was a Professor of Molecular and Cellular Biology at UC Davis for 23 years. He left UC Davis in 2001 to form BioElectroMed and was half-time Professor at Old Dominion University from 2004-2007 where he worked with Karl Schoenbach and Stephen Beebe on the use of nanosecond pulsed electric fields. He was elected Fellow of the American Association for the Advancement of Science in 1995 and Fellow in the American Institute for Medical and Biological Engineering in 2015. He has 134 publications and 7 patents. Dr. Nuccitelli has both an M.S. degree in Physics and a Ph.D. in Biological Sciences from Purdue University.

Job Titles:

• Director
• Member of the Audit Committee
• Member of the Compensation Committee
• Audit Committee
• Managing Partner of HSMR Advisors

Richard van den Broek was appointed to our Board of Directors in August 2020. Mr. van den Broek currently serves as managing partner of HSMR Advisors, LLC, a position he has held since February 2004, and as a director of PhaseBio Pharmaceuticals, Inc. since February 2019. He previously served on the boards of directors of Pharmacyclics, Inc. from December 2009 to April 2015, Response Genetics, Inc. from December 2010 to September 2015, Special Diversified Opportunities, Inc. from March 2008 to October 2015 and Celldex Therapeutics, Inc. from December 2014 to December 2016. Mr. van den Broek received an A.B. from Harvard University and is a Chartered Financial Analyst. Mr. van den Broek has extensive experience in the biotechnology sector and deep understanding of the global pharmaceutical market.

Job Titles:

• Chairman of the Board
• Director
• Executive Chairman of the Board of Directors
• Member of the Board of Directors
• Member of the Compensation Committee
• Member of the Nominating and Corporate Governance Committee
• Compensation Committee

Robert W. Duggan has been a director and chairman of the Board of Directors since November 2017. From 2015 Mr. Duggan has been CEO of Duggan Investments, a venture capital and public equity investment firm. His venture investments primarily focus on patient-friendly breakthrough solutions to complex diseases of aging. From 2008 to 2015, Mr. Duggan was Chairman, CEO and the largest investor in Pharmacyclics, a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of cancers. Pharmacyclics was sold to AbbVie for $21 billion in May of 2015. From 1990 to 2003, Mr. Duggan was Chairman of the Board of Computer Motion. From 1997 to 2003, Mr. Duggan also served as Chief Executive officer of Computer Motion. In June of 2003, Computer Motion merged with Intuitive Surgical [NASDAQ:ISRG]. This culminated in Computer Motion shareholders owning a 1/3 interest in the resulting business. From 2003 to 2011, Mr. Duggan served on the Board of Directors of Intuitive Surgical. Mr. Duggan received a U.S. Congressman's Medal of Merit from Ron Paul in 1985 and in 2000 he was named a Knight of the Legion D'Honor by President Jacques Chirac of France. He is a member of the University of California at Santa Barbara Foundation Board of Trustees. Mr. Duggan has also funded two Chairs in Mathematical, Life, and Physical Sciences as well as a Chair in Religious studies at the University of California at Santa Barbara. Member of the Nominating and Corporate Governance Committee Member of the Compensation Committee

Job Titles:

• Director
• Member of the Audit Committee
• Audit Committee
• Head of Marketing at Summit Therapeutics Inc

Ms. Spray currently serves as Head of Marketing at Summit Therapeutics Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel, precision medicinal therapies to solve serious unmet needs. Ms. Spray has over 25 years in the healthcare industry holding multiple executive roles which include Chief Marketing Officer of Aesthera Corporation (acquired by Solta Medical), where she focused on growth strategies and commercialization of their Isolaz photopneumatic system, and Vice President of Worldwide Marketing at Xlumena Inc. (acquired by Boston Scientific), where she led the development of their launch strategy for its endoscopic ultrasound guided transluminal system. Before this, Ms. Spray was Vice President of Worldwide Marketing at Intuitive Surgical [NASDAQ: ISRG] where she led early commercialization strategies into the US and international markets. In the late 1990s, Mr. Spray was Vice President and General Manager of the Radiosurgery and StealthNet Divisions of Medtronic, Inc. At Medtronic, she rebuilt infrastructure, redefined divisional focus, and developed B2B and B2C strategies for minimally invasive brain tumor treatments. Ms. Spray has been honored with many awards including a prestigious Telly Award and a Business Week Magazine Bronze award for product development and design. Ms. Spray received a BS in Business, Magna Cum Laude, Beta Gamma Sigma, from Arizona State University and graduated from the Competitive Strategic Marketing Program of Columbia University's Executive School of Business. Member of the Audit Committee

Job Titles:

• Member of the Management Team
• Vice President, Regulatory, Clinical and Quality Affairs

William Knape joined Pulse Biosciences in May 2018 as Vice President, Regulatory, Clinical, and Quality Affairs. Mr. Knape is an expert in regulatory affairs, clinical and quality assurance specializing in FDA and CE submissions with over 25 years working directly with the FDA in the life sciences industry, for both Rx and OTC products. His experience includes multiple regulatory submissions of 510(k)s, PMAs, IDEs, Pre-IDEs and Q-Sub meetings and international registration filings for a wide variety of innovative and novel medical device and IVD companies. Mr. Knape has managed numerous worldwide multicenter, clinical studies from first-in-man to Phase IV clinical programs. Prior to joining Pulse, Mr. Knape served in senior roles as Senior Director and Vice-President, where he helped develop key financial opportunities with strategic partners in multiple therapeutic areas including dermatology, oncology, aesthetics, diabetes, regenerative medicine, neurology, cardiology, and gastroenterology. Mr. Knape earned his B.Sc. in Psychology and B.Sc. in Medical Technology with an emphasis in bioengineering from the University of Wyoming and serves on the College of Health Sciences Advisory Board.